Buy APIs Raw Seratrodast Powder With Good Manufacturer Price
What is Seratrodast?
Seratrodast is a potent, long-acting, stereospecific thromboxane A2/prostaglandin endoperoxide receptor antagonist. The R-(+)-enantiomer of Seratrodast is the pharmacologically active moiety. Seratrodast appears to exert its anti-inflammatory effects through antagonism of the thromboxane A2 receptor (TP receptor). In addition, seratrodast blocks the broncho-constrictor effects of PGF2α, PGD2 and 9α,1lβ-PGF2 mediated through activation of thromboxane A2 receptor (TP receptor).
Seratrodast Certificate of Analysis
| Product name |
Seratrodast |
| CAS No. |
112665-43-7 |
Outer Packing |
1G/10G/1000GAluminumfoil bag |
| Production date |
16th Jan 2018 |
Shelf life |
15th Jan 2021 |
| Standard adopted |
Enterprise standard |
| Items of analysis |
Specification |
Results |
| Appearance |
Orange yellow or yellow crystalline powder |
yellow crystalline powder |
| liquid identification |
The product peak retention time should be consistent with the reference standard peak |
Complies |
| Solubility |
Soluble in ethyl acetate and touene, slightly soluble in ethanol,insoluble in water |
Complies |
| Melting point |
127-129℃ |
127.2-128℃ |
| Single impurity |
≤0.5% |
0.33% |
| Total impurity |
≤1% |
≤1% |
| Assay |
≥98.5% |
99.45% |
| Conclusion |
Qualified |
Seratrodast DOSAGE AND ADMINISTRATION
Average dose of 80 mg once daily is recommended
Seretra has been shown to be well-tolerated following repeated once daily oral doses of up to a maximum of 320 mg
In elderly patients, the treatment should be started with a lower dose of 40mg/day
Seratrodast Benefits
Unlike thromboxane synthase inhibitors such as ozagrel, seratrodast does not affect thrombus formation, time to occlusion and bleeding time.[6] Seratrodast has no effect on prothrombin time and activated partial thromboplastin time, thus ruling out any action on blood coagulation cascade.
Seratrodast Side Effects
The most frequently observed (0.1 to 5%) adverse reactions include elevated transaminases, nausea, loss of appetite, stomach discomfort, abdominal pain, diarrhea, constipation, dry mouth, taste disturbance, drowsiness, headache, dizziness, palpitations and malaise. Less than 0.1% of patients experienced vomiting, thrombocytopenia, epistaxis, bleeding tendency, insomnia, tremor, numbness, hot flushes and edema. All the adverse reactions reported were of mild to moderate severity, and resolved when the drug was discontinued.
